CR20190531A - Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue - Google Patents

Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Info

Publication number
CR20190531A
CR20190531A CR20190531A CR20190531A CR20190531A CR 20190531 A CR20190531 A CR 20190531A CR 20190531 A CR20190531 A CR 20190531A CR 20190531 A CR20190531 A CR 20190531A CR 20190531 A CR20190531 A CR 20190531A
Authority
CR
Costa Rica
Prior art keywords
dengue viral
compounds
indoline derivatives
viral replication
substituted indoline
Prior art date
Application number
CR20190531A
Other languages
English (en)
Inventor
Arnaud Didier M Marchand
Jean-François Bonfanti
Pierre Jean-Marie Bernard Raboisson
Bart Rudolf Romanie Kesteleyn
Dorothée Alice Marie-Eve Bardiot
BOECK Benoît Christian Albert Ghislain DE
Erwin Coesemans
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of CR20190531A publication Critical patent/CR20190531A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a derivados de indolina sustituidos, a métodos para prevenir o tratar infecciones virales por dengue mediante el uso de dichos compuestos y también se refiere a dichos compuestos para su uso como medicamento, más preferentemente, para su uso como medicamento para tratar o prevenir infecciones virales por dengue. La presente invención se refiere además a composiciones farmacéuticas o preparados combinados de los compuestos, a las composiciones o preparados para su uso como un medicamento, más preferentemente para la prevención o el tratamiento de infecciones virales por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
CR20190531A 2017-05-22 2018-05-18 Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue CR20190531A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17172247 2017-05-22
PCT/EP2018/063029 WO2018215316A1 (en) 2017-05-22 2018-05-18 Substituted indoline derivatives as dengue viral replication inhibitors

Publications (1)

Publication Number Publication Date
CR20190531A true CR20190531A (es) 2020-03-05

Family

ID=58745159

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190531A CR20190531A (es) 2017-05-22 2018-05-18 Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Country Status (29)

Country Link
US (2) US11053196B2 (es)
EP (1) EP3630724B1 (es)
JP (1) JP7179773B2 (es)
KR (1) KR102625991B1 (es)
CN (1) CN110753682B (es)
AR (1) AR111820A1 (es)
AU (1) AU2018274101C1 (es)
BR (1) BR112019024311A2 (es)
CA (1) CA3061026C (es)
CL (1) CL2019003309A1 (es)
CO (1) CO2019013042A2 (es)
CR (1) CR20190531A (es)
DK (1) DK3630724T3 (es)
EA (1) EA039702B1 (es)
EC (1) ECSP19083621A (es)
ES (1) ES2884157T3 (es)
HR (1) HRP20210724T1 (es)
HU (1) HUE054379T2 (es)
IL (1) IL270727B2 (es)
LT (1) LT3630724T (es)
MX (1) MX388870B (es)
PE (1) PE20200342A1 (es)
PH (1) PH12019502577A1 (es)
SI (1) SI3630724T1 (es)
TW (1) TWI771420B (es)
UA (1) UA125970C2 (es)
UY (1) UY37741A (es)
WO (1) WO2018215316A1 (es)
ZA (1) ZA201907713B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG11201808138YA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole derivatives as dengue viral replication inhibitors
MA44498A (fr) 2016-03-31 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EP3436004B1 (en) 2016-04-01 2024-12-11 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
EA202190046A1 (ru) 2018-06-19 2021-03-24 Новартис Аг N-замещенные производные тетрагидротиенопиридина и их применение
ES2942310T3 (es) 2018-12-27 2023-05-31 Servier Lab Inhibidores aza-heterobicíclicos de MAT2A y métodos de uso para el tratamiento del cáncer
US20240368153A1 (en) 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
JP2001520998A (ja) 1997-10-27 2001-11-06 イーライ・リリー・アンド・カンパニー インドールsPLA2阻害剤のモルホリノ−N−エチルエステルプロドラッグ
US6861504B2 (en) 2001-05-03 2005-03-01 Cbr, Inc. Compounds and methods for the modulation of CD154
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Hsp90阻害活性を有するプリン類似体
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US20060211698A1 (en) 2005-01-14 2006-09-21 Genelabs, Inc. Bicyclic heteroaryl derivatives for treating viruses
AU2006221080A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
AU2009256390A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
WO2010021378A1 (ja) 2008-08-22 2010-02-25 日本化薬株式会社 色素増感型光電変換素子
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
KR20120123678A (ko) 2010-01-15 2012-11-09 길리애드 사이언시즈, 인코포레이티드 플라비비리다에 바이러스의 억제제
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
KR20240017118A (ko) 2014-01-31 2024-02-06 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
PT3201176T (pt) 2014-10-01 2019-03-04 Janssen Pharmaceuticals Inc Derivados indol mono- ou dissubstituídos como inibidores da replicação viral do dengue
NO2721243T3 (es) 2014-10-01 2018-10-20
DK3201177T3 (en) 2014-10-01 2019-03-04 Janssen Pharmaceuticals Inc MONO OR DISUBSTITUTED INDOLES AS INHIBITORS OF DENGUE VIRUS REPLICATION
PH12017501272B1 (en) 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3370698B1 (en) 2015-11-03 2022-01-26 Zoetis Services LLC Sol-gel polymer composites and uses thereof
SG11201808138YA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole derivatives as dengue viral replication inhibitors
MY194647A (en) 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
MA44498A (fr) 2016-03-31 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
CA3015934A1 (en) 2016-04-01 2017-10-05 Basf Se Bicyclic compounds
EP3436004B1 (en) 2016-04-01 2024-12-11 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
KR102608405B1 (ko) 2016-04-01 2023-12-01 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102694879B1 (ko) 2016-04-01 2024-08-16 암젠 인크 Flt3에 대한 키메라 수용체 및 이의 사용 방법
BR112018070163A2 (pt) 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
PE20200342A1 (es) 2020-02-14
CL2019003309A1 (es) 2020-03-20
ES2884157T3 (es) 2021-12-10
ZA201907713B (en) 2022-03-30
US11053196B2 (en) 2021-07-06
IL270727B (en) 2022-11-01
UA125970C2 (uk) 2022-07-20
CN110753682B (zh) 2023-06-30
TWI771420B (zh) 2022-07-21
EA039702B1 (ru) 2022-03-01
TW201900611A (zh) 2019-01-01
CN110753682A (zh) 2020-02-04
US20200181083A1 (en) 2020-06-11
CO2019013042A2 (es) 2020-01-17
LT3630724T (lt) 2021-08-25
CA3061026A1 (en) 2018-11-29
AR111820A1 (es) 2019-08-21
AU2018274101B2 (en) 2022-04-21
WO2018215316A1 (en) 2018-11-29
PH12019502577A1 (en) 2020-07-20
EP3630724A1 (en) 2020-04-08
HUE054379T2 (hu) 2021-09-28
AU2018274101A1 (en) 2019-11-07
AU2018274101C1 (en) 2022-09-15
KR102625991B1 (ko) 2024-01-16
UY37741A (es) 2018-11-30
MX2019013878A (es) 2020-01-20
SI3630724T1 (sl) 2021-08-31
IL270727A (en) 2020-01-30
EP3630724B1 (en) 2021-04-28
IL270727B2 (en) 2023-03-01
DK3630724T3 (da) 2021-07-26
CA3061026C (en) 2024-01-30
JP7179773B2 (ja) 2022-11-29
EA201992784A1 (ru) 2020-04-23
HRP20210724T1 (hr) 2021-10-15
MX388870B (es) 2025-03-20
JP2020520950A (ja) 2020-07-16
ECSP19083621A (es) 2019-11-30
KR20200010355A (ko) 2020-01-30
US20210300868A1 (en) 2021-09-30
BR112019024311A2 (pt) 2020-07-28
US11702387B2 (en) 2023-07-18

Similar Documents

Publication Publication Date Title
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12018502016A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018500569A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017500571A1 (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY187068A (en) Indole derivatives as dengue viral replication inhibitors
PH12017500503A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors